ABSTRACT

The assessment of quality of life (QoL) has an important role in the management of patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapies which brought significant improvements in progression-free survival and QoL in recent years. Moreover, QoL is becoming one of the main factors influencing the choice of targeted agent, and QoL experienced during first-line treatment may affect the choice of the second-line therapy. QoL may not be affected only by treatment-related effects, but also mRCC symptoms and its clinical complications can alter QoL. It was aimed to review the studies performed to assess the QoL of the patients with mRCC receiving targeted therapy.